HEOR & Market Access Intelligence for Oncology
Inform decision-making from a reimbursement perspective
The Market Access Platform (MAP) unlocks critical insights and key decision drivers for Oncology drug therapy pricing. Integrating reimbursement, regulatory, and clinical data, the MAP enables users to link critical factors such as population restrictions in the marketing authorization with patient-reported outcomes in clinical trials. Capturing over two million points of data, the MAP supports evidence-driven decision making from early pipeline to value dossier creation, commercialization, and marketing.
Key Oncology questions MAP helps answer:
Clinical Trial Design
What primary endpoints were commonly used in Kidney Cancer?
How often have single-arm trials been used and how often are they successful in HTA evaluations?
Request a live demo
Complete the form below to request a live demo of the Market Access Platform.
What is the most plausible NICE ICER across all reviews in Breast Cancer?
What is the patient population considered in the cost-utility model for pembrolizumab?
Value Dossier Development
What is the patient population estimate for second-line Non-Small-Cell Lung Cancer in Germany?
What agencies are using patient-reported outcomes (PROs) in assessments for Gastric Cancer?